SCHEMBL26808599

SCHEMBL26808599

Cc1cccc(-c2nc(NS(=O)(=O)c3cnn(C)c3)nc(Oc3ccc(C4CCN(C)CC4)cc3)c2C(F)(F)F)c1C

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BRD4 O60885 4/20 0.35
▸ KDR P35968 2/20 0.34
▸ BRAF P15056 1/20 0.34
▸ SCN9A Q15858 3/20 0.33
▸ HTR1A P08908 5/20 0.33
▸ HTR7 P34969 5/20 0.33
▸ PTK2 Q05397 3/20 0.32
▸ JAK2 O60674 4/20 0.32
▸ MAP4K1 Q92918 1/20 0.32
▸ JAK3 P52333 2/20 0.32
▸ SLC8A1 P32418 1/20 0.31
▸ CCNT1 O60563 1/20 0.31
▸ CDK1 P06493 1/20 0.31
▸ CDK4 P11802 1/20 0.31
▸ CCNB1 P14635 1/20 0.31
▸ CCND1 P24385 1/20 0.31
▸ CCNE1 P24864 1/20 0.31
▸ CDK2 P24941 1/20 0.31
▸ CCND3 P30281 1/20 0.31
▸ CDK7 P50613 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24309772 0.94 HTR1A (0.35) BRD4KDRBRAFSCN9AHTR1A
SCHEMBL26808579 0.93 WEE1 (0.34) BRD4KDRBRAFSCN9AHTR1A
SCHEMBL26808563 0.92 BRD4 (0.34) BRD4KDRBRAFSCN9AHTR1A
SCHEMBL29567192 0.92 BRD4 (0.36) BRD4KDRBRAFSCN9AHTR1A
SCHEMBL26808522 0.92 BRD4 (0.36) BRD4KDRBRAFSCN9AHTR1A
SCHEMBL26808566 0.91 SCN9A (0.36) BRD4KDRBRAFSCN9AHTR1A
SCHEMBL26808596 0.90 HTR1A (0.36) KDRBRAFSCN9AHTR1AHTR7
SCHEMBL26808555 0.89 SCN9A (0.36) BRD4KDRBRAFSCN9AHTR1A
SCHEMBL26808605 0.89 HTR1A (0.34) BRD4KDRBRAFSCN9AHTR1A
SCHEMBL29567305 0.89 BRD4 (0.35) BRD4KDRBRAFSCN9AHTR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230373935-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS, SAN DIEGO 2023-11-23 — — US disclosed
US-20230373935-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS, SAN DIEGO 2023-11-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230373935-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR CFTR, SCNN1G, SCNN1B BRD4 1716/4885KDR 4439/4885BRAF 3030/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback